#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3798	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2152	500.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1447	1447	C	498	C	450	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6310	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4102	461.1	0	.	n	.	0	T695C	SNP	695	695	T	1273	1273	C	474	C	411	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6310	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4102	461.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1915	1915	A	523	A,G	480,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6310	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4102	461.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2549	2549	C	577	C,G,A	514,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6310	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4102	461.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3175	3175	T	552	T	505	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6310	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4102	461.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2623	2623	A	612	A	550	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	710	folP	852	852	100.0	folP.l6.c17.ctg.1	2032	104.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1270	1272	AGC	144;145;146	A,G;G;C	131,1;132;129	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1686	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3945	128.2	1	SNP	p	S91F	0	.	.	271	273	TCC	871	873	TCC	133;133;133	T;C;C	118;117;121	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1686	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3945	128.2	1	SNP	p	D95G	0	.	.	283	285	GAC	883	885	GAC	133;132;131	G,A;A;C	120,1;121;121	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1686	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3945	128.2	1	SNP	p	D95N	0	.	.	283	285	GAC	883	885	GAC	133;132;131	G,A;A;C	120,1;121;121	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	688	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1849	111.5	1	SNP	p	G45D	1	.	.	133	135	GAC	705	707	GAC	160;160;161	G;A;C	146;143;151	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	456	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1384	98.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1600	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3356	143.0	1	SNP	p	D86N	0	.	.	256	258	GAC	773	775	GAC	157;157;156	G;A,C;C	138;137,2;142	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1600	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3356	143.0	1	SNP	p	S87W	0	.	.	259	261	AGT	776	778	AGT	156;156;155	A,C;G;T	136,1;139;137	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1600	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3356	143.0	1	SNP	p	S87I	0	.	.	259	261	AGT	776	778	AGT	156;156;155	A,C;G;T	136,1;139;137	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1600	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3356	143.0	1	SNP	p	S87R	0	.	.	259	261	AGT	776	778	AGT	156;156;155	A,C;G;T	136,1;139;137	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1600	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3356	143.0	1	SNP	p	S88P	0	.	.	262	264	TCC	779	781	TCC	154;154;153	T;C;C	140;138;141	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1414	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2982	141.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1767	1769	GGC	177;178;176	G;G;C,A	158;160;158,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1478	1480	GCA	181;182;179	G,A;C,A;A	165,1;165,1;161	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1481	1483	ATC	178;178;177	A;T;C	169;159;161	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1493	1495	GTG	178;178;178	G;T;G	161;159;157	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1493	1495	GTG	178;178;178	G;T;G	161;159;157	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1997	1999	ACC	124;124;124	A;C;C	112;108;112	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2051	2053	GCG	123;123;123	G;C,G;G,C	102;100,1;102,1	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2051	2053	GCG	123;123;123	G;C,G;G,C	102;100,1;102,1	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2174	2176	GGC	122;122;123	G,C;G;C,T	103,1;106;102,2	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2183	2185	GGC	130;129;130	G,A,T;G;C,G	109,1,1;110;110,2	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2828	118.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2201	2203	CCG	131;131;131	C,G;C,T;G	104,1;112,1;110	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1498	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3731	120.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	910	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2373	115.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	851	851	C	135	C	129	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	G38E	NONSYN	112	114	GGA	838	840	GAA	154;155;157	G;A;A	138;137;145	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	V45A	NONSYN	133	135	GTT	859	861	GCT	146;146;146	G,T;C,A,T;T	135,1;134,1,1;134	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	985	987	GCT	176;176;175	G;C;T,G	156;154;153,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	991	993	AGC	175;175;175	A;G;C	156;155;157	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	1083	1084	CG	169;170	C;G	152;154	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	1086	1088	CAG	169;167;168	C,A;A;G	151,1;150;151	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	1090	1092	AAA	169;169;169	A;A,G,C;A	152;153,1,1;154	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1153	1155	GAA	167;167;167	G,A;A,G;A	150,1;147,1;151	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1177	1179	GCA	165;165;166	G;C;A	146;148;147	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1285	1287	CGA	155;155;155	C;G;A	144;145;140	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1360	1362	GAT	168;168;168	G;A;T	149;149;152	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1363	1365	GGT	169;168;168	G;G,A;T,G	152;153,1;153,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1372	1374	CAT	167;168;168	C;A;T	153;154;151	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1378	1380	ATG	164;164;164	A;T;G	152;152;152	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1492	1494	GCA	139;139;139	G;C;A	132;133;134	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1495	1497	ACG	137;136;136	A;C;G	129;129;129	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1498	1500	GGG	136;136;136	G,A;G;G	128,1;130;130	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1501	1503	GTT	136;137;137	G;T;T	129;129;127	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1561	1563	GTA	147;145;146	G;T;A	130;129;130	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1600	1602	ACT	153;152;152	A;C;T	135;127;133	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1606	1608	GAT	155;155;155	G;A;T	135;136;136	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1609	1611	GAT	155;153;153	G;A;T	137;135;132	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1615	1617	AAC	155;156;156	A;A;C,A	134;136;132,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1618	1620	CAC	156;156;156	C;A;C	132;137;134	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	1	SNP	p	G120K	1	.	.	358	360	AAG	1083	1085	CGG	169;170;169	C;G;G,T	152;154;148,1	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	1	SNP	p	A121D	1	.	.	361	363	GAC	1086	1089	CGC	169;168;169	C,A;G;C	151,1;151;153	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	798	porB1b	1047	1047	96.47	porB1b.l15.c4.ctg.1	2117	111.9	1	SNP	p	D121N	0	.	.	361	363	GAC	1086	1089	CGC	169;168;169	C,A;G;C	151,1;151;153	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2358	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5366	131.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2237	2239	AAT	126;126;126	A;A;T,G	117;113;115,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	236	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1609	43.9	1	SNP	p	V57M	1	.	.	169	171	ATG	801	803	ATG	84;84;84	A;T;G	80;81;81	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
